ionis-pkkrx
Nucleic acidexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2017 (NCT03108469)
Timeline
Indications
Mechanism of action
- Plasma kallikreinANTISENSE INHIBITOR
KLKB1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ionis-pkkrx
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04307381 | Phase 2 | May 31, 2020 | Ionis Pharmaceuticals, Inc. |
| NCT04030598 | Phase 2 | Sep 30, 2019 | Ionis Pharmaceuticals, Inc. |
| NCT03263507 | Phase 1 | Aug 28, 2017 | Ionis Pharmaceuticals, Inc. |
| NCT03108469 | Phase 2 | Jul 31, 2017 | Clinvest, Harvard University, Ionis Pharmaceuticals, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | For profit | 4 | 3 | 2 | 2017 |
| Clinvest | For profit | 1 | 0 | 1 | 2017 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1